

Assessing and reporting heterogeneity in treatment effects

Trials

11, 85

DOI: [10.1186/1745-6215-11-85](https://doi.org/10.1186/1745-6215-11-85)

Citation Report

#	ARTICLE	IF	CITATIONS
1	President's Page: Employing Shared Decision-Making Models to Improve Care and Patient Value: A Cardiovascular Professional Initiative. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2046-2048.	1.2	15
2	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. <i>Trials</i> , 2011, 12, 252.	0.7	38
3	The assessment of heterogeneity is mandatory in clinical trials and systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 452-452.	2.4	0
4	Random Treatment Assignment Using Mathematical Equipoise for Comparative Effectiveness Trials. <i>Clinical and Translational Science</i> , 2011, 4, 10-16.	1.5	7
5	A CTSA Agenda to Advance Methods for Comparative Effectiveness Research. <i>Clinical and Translational Science</i> , 2011, 4, 188-198.	1.5	28
6	Guidelines for the Older Adult With CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 162-165.	2.1	29
7	Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials. <i>Journal of General Internal Medicine</i> , 2011, 26, 783-790.	1.3	324
8	Inclusion and Analysis of Older Adults in RCTs. <i>Journal of General Internal Medicine</i> , 2011, 26, 832-832.	1.3	2
9	The Risk of Paradoxical Embolism (RoPE) Study: Developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. <i>Trials</i> , 2011, 12, 185.	0.7	95
10	Registration of epidemiological studies: benefits and risks. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1005-1008.	0.9	0
11	Predicting response to a cognitive-behavioral approach to treating low back pain: Secondary analysis of the BeST data set. <i>Arthritis Care and Research</i> , 2011, 63, 1271-1279.	1.5	20
12	Estimating treatment effects for individual patients based on the results of randomised clinical trials. <i>BMJ: British Medical Journal</i> , 2011, 343, d5888-d5888.	2.4	120
13	The Problem of Subgroup Analyses: An Example from a Trial on Ruptured Intracranial Aneurysms. <i>American Journal of Neuroradiology</i> , 2011, 32, 633-636.	1.2	33
14	The Clinical Research Enterprise. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 604.	3.8	15
15	Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, 1557-1564.	1.6	60
16	Individual and Population Benefits of Daily Aspirin Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 268-275.	0.9	30
17	Clinical Trial Subgroups. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 266-267.	0.9	1
18	Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate Cancer. <i>Journal of Oncology Practice</i> , 2011, 7, e16s-e24s.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Individualized Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2011, 8, e1001058.	3.9	44
20	Multiple Micronutrient Interventions Are Efficacious, but Research on Adequacy, Plausibility, and Implementation Needs Attention. <i>Journal of Nutrition</i> , 2012, 142, 205S-209S.	1.3	19
21	A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. <i>New England Journal of Medicine</i> , 2012, 366, 1414-1422.	13.9	616
22	Evidence-Based Medicine Versus Personalized Medicine. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 153-164.	0.7	70
23	Effect of inborn vs. outborn delivery on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy: secondary analyses of the NICHD whole-body cooling trial. <i>Pediatric Research</i> , 2012, 72, 414-419.	1.1	39
24	From Methods To Policy: A "one-size-fits-all" policy ignores patient heterogeneity. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 119-120.	0.6	4
25	Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 263-270.	0.6	14
26	Treatment matching for obesity: identifying mediators of psychosocial and behavioral intervention components. <i>International Journal of Obesity Supplements</i> , 2012, 2, S23-S25.	12.5	3
27	Standard 6: Age Groups for Pediatric Trials. <i>Pediatrics</i> , 2012, 129, S153-S160.	1.0	375
28	Risk Models and Patient-Centered Evidence. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1585.	3.8	37
29	Lessons learned from the first wave of aging with HIV. <i>Aids</i> , 2012, 26, S11-S18.	1.0	39
30	Is Every Defect Really a Treasure?. <i>Annals of Internal Medicine</i> , 2012, 156, 664.	2.0	2
31	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. <i>Lancet</i> , 2012, 379, 2352-2363.	6.3	1,018
32	From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. <i>BMC Medical Research Methodology</i> , 2012, 12, 185.	1.4	48
33	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93
34	Individual differences and evidence-based psychopharmacology. <i>BMC Medicine</i> , 2012, 10, 110.	2.3	15
35	How Well Do Randomized Trials Inform Decision Making: Systematic Review Using Comparative Effectiveness Research Measures on Acupuncture for Back Pain. <i>PLoS ONE</i> , 2012, 7, e32399.	1.1	41
36	Reporting Guidelines. <i>American Journal of Preventive Medicine</i> , 2012, 43, e31-e42.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Can Observational Studies Approximate RCTs?. Value in Health, 2012, 15, 215-216.	0.1	9
38	Personalised medicine: not just in our genes. BMJ, The, 2012, 344, e2161-e2161.	3.0	39
39	COMPREHENSIVE REVIEW OF FACTORS IMPLICATED IN THE HETEROGENEITY OF RESPONSE IN DEPRESSION. Depression and Anxiety, 2012, 29, 340-354.	2.0	68
40	Skills, Knowledge, and Prediction. American Journal of Cardiology, 2012, 110, 161.	0.7	0
41	Scientific rigour in psycho-oncology trials: why and how to avoid common statistical errors. Psycho-Oncology, 2013, 22, 499-505.	1.0	11
42	Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. Journal of Clinical Epidemiology, 2013, 66, S21-S28.	2.4	184
43	Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model. Statistics in Medicine, 2013, 32, 4906-4923.	0.8	26
44	Reporting quality of survival analyses in medical journals still needs improvement. A minimal requirements proposal. Journal of Clinical Epidemiology, 2013, 66, 1340-1346.e5.	2.4	29
45	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	6.3	105
47	A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. Journal of Clinical Epidemiology, 2013, 66, 818-825.	2.4	101
49	Evidence based medicine and patient centered medicine: Some thoughts on their integration. Revista Clínica Española, 2013, 213, 460-464.	0.3	8
50	Differences between opioids: pharmacological, experimental, clinical and economical perspectives. British Journal of Clinical Pharmacology, 2013, 75, 60-78.	1.1	150
51	The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. Journal of Comparative Effectiveness Research, 2013, 2, 605-618.	0.6	2
52	Conceptual, Methodological, and Ethical Problems in Communicating Uncertainty in Clinical Evidence. Medical Care Research and Review, 2013, 70, 14S-36S.	1.0	138
53	Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 27-34.	0.9	28
54	An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology, 2013, 81, 619-625.	1.5	468
55	Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genetics in Medicine, 2013, 15, 415-422.	1.1	29
56	Limitations of Medical Research and Evidence at the Patient-Clinician Encounter Scale. Chest, 2013, 143, 1127-1135.	0.4	11

#	ARTICLE	IF	CITATIONS
57	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 149-163.	0.9	188
58	What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e87987.	1.1	854
59	A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2014, 6, 437.	0.9	40
60	Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2014, 112, 16-25.	1.8	3
61	The Good, the Bad, and the Different: A Primer on Aspects of Heterogeneity of Treatment Effects. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 555-563.	2.2	8
62	Cardiovascular Risk and Statin Use in the United States. <i>Annals of Family Medicine</i> , 2014, 12, 215-223.	0.9	59
63	Prediction of responders for outcome measures of Locomotor Experience Applied Post Stroke trial. <i>Journal of Rehabilitation Research and Development</i> , 2014, 51, 39-50.	1.6	47
64	Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. <i>PLoS Medicine</i> , 2014, 11, e1001655.	3.9	75
65	Moneyball, Gambling, and the New Cholesterol Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 311-314.	0.9	12
66	From mechanism to empiricism: the evolution of heterogeneity of treatment effects. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 459-461.	0.6	0
67	Why try to predict ICU outcomes?. <i>Current Opinion in Critical Care</i> , 2014, 20, 544-549.	1.6	36
68	Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 163-169.	0.9	70
69	Lag Time to Benefit for Preventive Therapies. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1567.	3.8	3
70	Refining the American guidelines for prevention of cardiovascular disease. <i>Lancet, The</i> , 2014, 383, 598.	6.3	1
71	A Framework for Crafting Clinical Practice Guidelines that are Relevant to the Care and Management of People with Multimorbidity. <i>Journal of General Internal Medicine</i> , 2014, 29, 670-679.	1.3	125
72	Multimorbidity and Evidence Generation. <i>Journal of General Internal Medicine</i> , 2014, 29, 653-660.	1.3	54
73	Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. <i>European Heart Journal</i> , 2014, 35, 837-843.	1.0	54
74	A randomized trial of antibiotic prophylaxis for the prevention of surgical site infection after open mesh-plug hernia repair. <i>American Journal of Surgery</i> , 2014, 207, 476-484.	0.9	35

#	ARTICLE	IF	CITATIONS
75	Accuracy of the Spot Sign on Computed Tomography Angiography as a Predictor of Haematoma Enlargement after Acute Spontaneous Intracerebral Haemorrhage: A Systematic Review. <i>Cerebrovascular Diseases</i> , 2014, 37, 268-276.	0.8	33
76	Individualizing treatment choices using quantitative methods. <i>American Heart Journal</i> , 2014, 168, 607-610.	1.2	10
77	Statistical analysis plan for the Stroke Oxygen Study (SO2S): a multi-center randomized controlled trial to assess whether routine oxygen supplementation in the first 72 hours after a stroke improves long-term outcome. <i>Trials</i> , 2014, 15, 229.	0.7	2
78	Development of Clinical Practice Guidelines. <i>Annual Review of Clinical Psychology</i> , 2014, 10, 213-241.	6.3	69
79	Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. <i>Diabetes Care</i> , 2014, 37, 634-643.	4.3	104
80	Transesophageal Echocardiography in Cryptogenic Stroke and Patent Foramen Ovale. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 125-131.	1.3	58
81	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , The, 2014, 383, 2008-2017.	6.3	194
82	Tight Glycemic Control After Pediatric Cardiac Surgery in High-Risk Patient Populations. <i>Circulation</i> , 2014, 129, 2297-2304.	1.6	40
83	Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1204-1213.	2.5	177
84	A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 147-153.	2.3	32
85	Separating signal from noise: the challenge of identifying useful biomarkers in sepsis. <i>Critical Care</i> , 2014, 18, 121.	2.5	1
86	Association of Dietary, Circulating, and Supplement Fatty Acids With Coronary Risk. <i>Annals of Internal Medicine</i> , 2014, 161, 454.	2.0	2
87	Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. <i>Statistics in Medicine</i> , 2014, 33, 4695-4708.	0.8	26
88	Which stroke patients gain most from intermittent pneumatic compression: further analyses of the CLOTS 3 trial. <i>International Journal of Stroke</i> , 2015, 10, 103-107.	2.9	4
89	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: Table A1. <i>Evidence-Based Medicine</i> , 2015, 20, 162-169.	0.6	7
90	La heterogeneidad en los metaanálisis, ¿es nuestra mejor aliada?. <i>Colombian Journal of Anesthesiology</i> , 2015, 43, 176-178.	0.5	1
91	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 217.	1.8	36
92	Three simple rules to ensure reasonably credible subgroup analyses. <i>BMJ</i> , The, 2015, 351, h5651.	3.0	157

#	ARTICLE	IF	CITATIONS
93	Heterogeneity in meta-analyses: Our greatest ally? Colombiana Journal of Anesthesiology, 2015, 43, 176-178.	0.5	1
94	Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions. PLoS ONE, 2015, 10, e0118991.	1.1	41
95	Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 372, 2197-2206.	13.9	541
96	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer, 2015, 112, 1888-1894.	2.9	272
97	Personalising results from large trials. BMJ, The, 2015, 350, h553-h553.	3.0	1
98	Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department. Annals of Emergency Medicine, 2015, 66, 322-333.e31.	0.3	35
99	Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease – Results from EUROPA. International Journal of Cardiology, 2015, 182, 194-199.	0.8	11
100	Patient-centric HTA: different strokes for different folks. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 591-597.	0.7	23
101	Heterogeneity in meta-analyses: Our greatest ally?. Colombiana Journal of Anesthesiology, 2015, 43, 176-178.	0.5	0
102	Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination in Community-Dwelling Veterans. Clinical Infectious Diseases, 2015, 61, 171-176.	2.9	54
103	Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ, The, 2015, 350, h454-h454.	3.0	101
104	On the Undiffusion of Established Practices. JAMA Internal Medicine, 2015, 175, 809.	2.6	51
105	Re-evaluating the Approach to Transfusions after Cardiac Surgery. New England Journal of Medicine, 2015, 372, 1069-1070.	13.9	8
106	Thrombectomy for Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2015, 314, 1803.	3.8	5
107	Clinical Prediction Models for Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 368-375.	0.9	79
108	Realizing the Potential of Clinical Risk Prediction Models. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 332-334.	0.9	13
109	A Systematic Assessment of the Surviving Sepsis Campaign's Evidence Supporting the Care of Patients with Severe Sepsis on the Wards. Annals of the American Thoracic Society, 2015, 12, 956-958.	1.5	6
110	Managing physician lipid management: a population wide, risk-based decision support approach. Israel Journal of Health Policy Research, 2015, 4, 34.	1.4	0

#	ARTICLE	IF	CITATIONS
111	Reply: Comment on "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer". British Journal of Cancer, 2015, 113, 1635-1635.	2.9	127
112	Incident disability in older adults: prediction models based on two British prospective cohort studies. Age and Ageing, 2015, 44, 275-282.	0.7	12
113	Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions. Journal of Clinical Epidemiology, 2015, 68, 1366-1374.	2.4	34
114	A predictive model to identify patients with suspected acute coronary syndromes at high risk of cardiac arrest or in-hospital mortality: An IMMEDIATE Trial sub-study. IJC Heart and Vasculature, 2015, 9, 37-42.	0.6	0
115	Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (<scp>BPH</scp>). BJU International, 2015, 115, 308-318.	1.3	40
116	Are cardiovascular trial results systematically different between North America and Europe? A study based on intra-meta-analysis comparisons. Archives of Cardiovascular Diseases, 2015, 108, 23-38.	0.7	4
117	Covariate adjustment had similar benefits in small and large randomized controlled trials. Journal of Clinical Epidemiology, 2015, 68, 1068-1075.	2.4	33
118	Predicting the Effects of Blood Pressure "Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus. Hypertension, 2015, 65, 115-121.	1.3	24
119	Individualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposal. Critical Care, 2016, 20, 218.	2.5	24
120	Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes, Obesity and Metabolism, 2016, 18, 1120-1127.	2.2	9
121	A multivariable model to guide the decision for pessary placement to prevent preterm birth in women with a multiple pregnancy: a secondary analysis of the ProTWIN trial. Ultrasound in Obstetrics and Gynecology, 2016, 48, 48-55.	0.9	14
122	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetology and Metabolic Syndrome, 2016, 8, 37.	1.2	9
123	Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. International Journal of Epidemiology, 2016, 45, dyw118.	0.9	89
124	A systematic review of randomized controlled trials and reviews in the management of "ventral" hernias. Journal of Surgical Research, 2016, 204, 311-318.	0.8	8
125	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 213-221.	0.9	12
126	Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN). Lancet Neurology, The, 2016, 15, 685-694.	4.9	100
127	Home-based interventions for black patients with uncontrolled hypertension: a cluster randomized controlled trial. Journal of Comparative Effectiveness Research, 2016, 5, 155-168.	0.6	11
128	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, 59, 2603-2612.	2.9	8

#	ARTICLE	IF	CITATIONS
129	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure – Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	0.8	6
130	Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. <i>American Heart Journal</i> , 2016, 178, 190-197.	1.2	14
131	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
132	Improving Prognostic Web Calculators: Violation of Preferential Risk Independence. <i>Journal of Palliative Medicine</i> , 2016, 19, 1325-1330.	0.6	1
133	Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1868-1877.	1.2	128
134	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. <i>Current Epidemiology Reports</i> , 2016, 3, 277-284.	1.1	10
135	Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. <i>International Journal of Epidemiology</i> , 2016, 45, dyw125.	0.9	66
136	Heterogeneity of therapeutic effects. <i>Atherosclerosis</i> , 2016, 255, 124-125.	0.4	0
137	EMMIE and engineering: What works as evidence to improve decisions?. <i>Evaluation</i> , 2016, 22, 304-322.	0.7	12
138	Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. <i>BMJ, The</i> , 2016, 355, i5826.	3.0	56
139	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. <i>BMJ, The</i> , 2016, 353, i2607.	3.0	28
140	A systematic approach to designing statistically powerful heteroscedastic 2x2 factorial studies while minimizing financial costs. <i>BMC Medical Research Methodology</i> , 2016, 16, 114.	1.4	1
141	No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals. <i>Trials</i> , 2016, 17, 320.	0.7	33
142	Rebuttal From Dr Tillotson. <i>Chest</i> , 2016, 149, 1133-1135.	0.4	0
143	Rebuttal From Dr Courtright. <i>Chest</i> , 2016, 149, 1132-1133.	0.4	0
144	Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the ‘‘Optimal’’ Oral Anticoagulant for Atrial Fibrillation. <i>Value in Health</i> , 2016, 19, 661-669.	0.1	3
145	Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes. <i>BMC Medical Research Methodology</i> , 2016, 16, 20.	1.4	66
146	Tailoring treatments using treatment effect modification. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 355-362.	0.9	12

#	ARTICLE	IF	CITATIONS
147	Field Synopsis of the Role of Sex in Stroke Prediction Models. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	11
148	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , 2016, 55, 122-130.	1.3	32
149	QUINT: A tool to detect qualitative treatmentâ€™s subgroup interactions in randomized controlled trials. <i>Psychotherapy Research</i> , 2016, 26, 612-622.	1.1	11
150	Empirical Treatment Effectiveness Models for Binary Outcomes. <i>Medical Decision Making</i> , 2016, 36, 101-114.	1.2	2
151	The Problem and Promise of Prognosis Research. <i>JAMA Pediatrics</i> , 2016, 170, 411.	3.3	14
152	A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity. <i>Journal of Clinical Epidemiology</i> , 2016, 75, 56-65.	2.4	129
153	CHOosing Options for Insomnia in Cancer Effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia. <i>Contemporary Clinical Trials</i> , 2016, 47, 349-355.	0.8	23
154	Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 368-375.	0.4	39
155	The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. <i>Journal of Wound Care</i> , 2017, 26, S4-S15.	0.5	32
156	Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data. <i>Evaluation Review</i> , 2017, 41, 357-388.	0.4	34
157	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017, 37, 790-801.	1.2	9
158	Transforming the National Surgical Quality Improvement Program to the Delivery of Precision Medicine to Improve the Value of Surgical Care. <i>JAMA Surgery</i> , 2017, 152, 815.	2.2	3
159	Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. <i>Journal of Veterinary Internal Medicine</i> , 2017, 31, 970-978.	0.6	18
160	Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid. <i>BMJ Open</i> , 2017, 7, e013699.	0.8	7
161	Personalizing the Intensity of Blood Pressure Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	37
162	Individualized Risk Estimates From Population Data: Should We Stop Creating Models and Start Engaging Patients?. <i>Journal of Cardiac Failure</i> , 2017, 23, 278-279.	0.7	3
163	Ghrelin, CCK, GLP-1, and PYY(3â€™-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. <i>Physiological Reviews</i> , 2017, 97, 411-463.	13.1	414
164	Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 22-36.	1.8	111

#	ARTICLE	IF	CITATIONS
165	Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment. <i>Annals of Internal Medicine</i> , 2017, 166, 354.	2.0	35
166	A Tale of Two Trials: Reconciling Differences in Results by Exploring Heterogeneous Treatment Effects. <i>Annals of Internal Medicine</i> , 2017, 166, 370.	2.0	2
167	Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 169-176.	0.3	9
168	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. <i>JAMA Neurology</i> , 2017, 74, 1319.	4.5	21
169	Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone Hydrochloride?. <i>JAMA Neurology</i> , 2017, 74, 1294.	4.5	0
170	A randomised controlled trial of an intervention delivered by app instant messaging to increase the acceptability of effective contraception among young people in Tajikistan: study protocol. <i>BMJ Open</i> , 2017, 7, e017606.	0.8	6
171	Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 808-815.	5.5	81
172	Impact of Telemonitoring on Health Status. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	25
173	Lessons Learned from Two Decades of Anticancer Drugs. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 852-872.	4.0	74
174	An Interoperable Similarity-based Cohort Identification Method Using the OMOP Common Data Model Version 5.0. <i>Journal of Healthcare Informatics Research</i> , 2017, 1, 1-18.	5.3	3
175	The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. <i>American Journal of Epidemiology</i> , 2017, 185, 842-852.	1.6	15
176	An approach to addressing subpopulation considerations in systematic reviews: the experience of reviewers supporting the U.S. Preventive Services Task Force. <i>Systematic Reviews</i> , 2017, 6, 41.	2.5	14
177	Can Knowledge About Heterogeneity in Treatment Effects Help Us Choose Wisely?. <i>Annals of Internal Medicine</i> , 2017, 166, 141.	2.0	16
178	Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients: a randomized double-blind placebo-controlled trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 2317-2324.	1.3	17
179	Bayesian Nonparametric Clustering of Patients with Advanced Cancer on Anxiety and Depression. , 2017, , .		2
180	Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials. <i>BMJ: British Medical Journal</i> , 2017, 357, j1710.	2.4	98
181	The development of CHAMP: a checklist for the appraisal of moderators and predictors. <i>BMC Medical Research Methodology</i> , 2017, 17, 173.	1.4	20
182	An intervention delivered by text message to increase the acceptability of effective contraception among young women in Palestine: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 454.	0.7	11

#	ARTICLE	IF	CITATIONS
183	Health-related quality of life among older patients following an emergency department visit and emergency department-to-home coaching intervention: A randomized controlled trial. <i>International Journal of Care Coordination</i> , 2017, 20, 162-170.	0.3	6
184	The Pros of Publishing Standalone Clinical Trial Protocols in Anesthesiology Journals. <i>Anesthesia and Analgesia</i> , 2018, 126, 1441-1443.	1.1	0
185	Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. <i>Journal of Clinical Epidemiology</i> , 2018, 100, 22-31.	2.4	27
186	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. <i>Rheumatology</i> , 2018, 57, 1364-1369.	0.9	3
187	Nursing research in heart failure care: a position statement of the american association of heart failure nurses (AAHFN). <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2018, 47, 169-175.	0.8	15
188	Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , 2018, 38, 487-494.	1.2	16
189	Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2018, 41, 604-612.	4.3	51
190	Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. <i>American Journal of Medicine</i> , 2018, 131, 676-683.e2.	0.6	3
191	The proposed $\hat{\alpha}$ -concordance-statistic for benefit TM provided a useful metric when modeling heterogeneous treatment effects. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 59-68.	2.4	55
192	Whom to Treat for High Blood Pressure—Time for a Precision Approach. <i>JAMA Internal Medicine</i> , 2018, 178, 37.	2.6	0
193	Cultural primer for cardiometabolic health: health disparities, structural factors, community, pathways to improvement, and clinical applications. <i>Postgraduate Medicine</i> , 2018, 130, 200-221.	0.9	7
194	Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*. <i>Critical Care Medicine</i> , 2018, 46, 21-28.	0.4	72
195	Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. <i>PLoS ONE</i> , 2018, 13, e0208795.	1.1	20
196	Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. <i>BMJ: British Medical Journal</i> , 2018, 363, k4245.	2.4	234
197	Equivalence Tests in Subgroup Analyses. <i>ICSA Book Series in Statistics</i> , 2018, , 201-238.	0.0	1
198	The prediction of therapy-benefit for individual cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , 2018, 29, 436-444.	1.2	21
199	Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain. <i>JAMA Internal Medicine</i> , 2018, 178, 1368.	2.6	68
200	Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials. <i>Trials</i> , 2018, 19, 382.	0.7	12

#	ARTICLE	IF	CITATIONS
201	Searching for an Optimal Systolic Blood Pressure Target: A Balance of Benefits and Risks. Canadian Journal of Cardiology, 2018, 34, 1543-1545.	0.8	0
202	The "average" treatment effect: A construct ripe for retirement. A commentary on Deaton and Cartwright. Social Science and Medicine, 2018, 210, 77-82.	1.8	39
203	Analytical Approaches for Post-Authorization Safety Studies. , 2018, , 167-221.		0
204	The Role of Comparative Effectiveness Research. , 2018, , 269-292.		3
205	Risk-Targeted Lung Cancer Screening. Annals of Internal Medicine, 2018, 168, 161.	2.0	85
206	A randomized controlled trial of an intervention delivered by mobile phone app instant messaging to increase the acceptability of effective contraception among young people in Tajikistan. Reproductive Health, 2018, 15, 28.	1.2	27
207	Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003971.	0.9	14
208	Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. Headache, 2018, 58, 218-229.	1.8	41
209	The study of effect moderation in youth suicide-prevention studies. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 1303-1310.	1.6	10
210	Development and evaluating multimarker models for guiding treatment decisions. BMC Medical Informatics and Decision Making, 2018, 18, 52.	1.5	3
211	Design and estimation in clinical trials with subpopulation selection. Statistics in Medicine, 2018, 37, 4335-4352.	0.8	18
212	Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathologica, 2018, 136, 377-388.	3.9	112
213	Risk-Based Data Monitoring: Quality Control in Central Nervous System (CNS) Clinical Trials. Therapeutic Innovation and Regulatory Science, 2019, 53, 176-182.	0.8	2
214	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2019, 105, 1156-1163.	2.3	22
215	Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2019, 8, e012749.	1.6	29
216	Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. Journal of Clinical Epidemiology, 2019, 114, 72-83.	2.4	53
217	Selection of anterior circulation acute stroke patients for mechanical thrombectomy. Journal of Neurology, 2019, 266, 2620-2628.	1.8	8
218	Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. BMC Medicine, 2019, 17, 188.	2.3	8

#	ARTICLE	IF	CITATIONS
219	Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2074-2084.	1.2	19
220	Pragmatic trials and implementation science: grounds for divorce?. <i>BMC Medical Research Methodology</i> , 2019, 19, 176.	1.4	29
221	Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views. <i>Npj Digital Medicine</i> , 2019, 2, 81.	5.7	3
222	Graded exposure treatment for adolescents with chronic pain (GET Living): Protocol for a randomized controlled trial enhanced with single case experimental design. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100448.	0.5	17
223	Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel. <i>Frontiers in Oncology</i> , 2019, 9, 789.	1.3	11
224	Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. <i>Cancer Biology and Medicine</i> , 2019, 16, 341.	1.4	5
225	Improving the reporting quality of intervention trials addressing the inter-individual variability in response to the consumption of plant bioactives: quality index and recommendations. <i>European Journal of Nutrition</i> , 2019, 58, 49-64.	1.8	9
226	Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. <i>Obesity</i> , 2019, 27, 288-294.	1.5	44
227	A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 159-167.	2.4	19
228	Intensive Glucose Control in Patients with Type 2 Diabetes – 15-Year Follow-up. <i>New England Journal of Medicine</i> , 2019, 380, 2215-2224.	13.9	173
229	Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine. <i>Breast</i> , 2019, 46, 90-94.	0.9	6
230	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. <i>Lancet Neurology</i> , The, 2019, 18, 643-652.	4.9	68
231	Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. <i>Critical Care</i> , 2019, 23, 156.	2.5	27
232	A randomized controlled trial of an intervention delivered by mobile phone text message to increase the acceptability of effective contraception among young women in Palestine. <i>Trials</i> , 2019, 20, 228.	0.7	24
233	Estimating patient-specific treatment advantages in the –Treatment for Adolescents with Depression Study–™. <i>Journal of Psychiatric Research</i> , 2019, 112, 61-70.	1.5	8
234	Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005010.	0.9	33
235	How context can impact clinical trials: a multi-country qualitative case study comparison of diagnostic biomarker test interventions. <i>Trials</i> , 2019, 20, 111.	0.7	10
236	Improving anti-platelet therapy adherence in the Veterans Health Administration: A randomized multi-site hybrid effectiveness-implementation study protocol. <i>Contemporary Clinical Trials</i> , 2019, 77, 104-110.	0.8	4

#	ARTICLE	IF	CITATIONS
237	Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. <i>Blood</i> , 2019, 134, 2354-2360.	0.6	41
238	Sample enrichment for clinical trials to show delay of onset in huntington disease. <i>Movement Disorders</i> , 2019, 34, 274-280.	2.2	10
239	A Patientâ€Centered Approach to Comparative Effectiveness Research Focused on Older Adults: Lessons From the Patientâ€Centered Outcomes Research Institute. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 21-28.	1.3	13
240	The shrinking scope of pragmatic trials: a methodological reflection on their domain of applicability. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 71-76.	2.4	7
241	Interpretation of CVD risk predictions in clinical practice: Mission impossible?. <i>PLoS ONE</i> , 2019, 14, e0209314.	1.1	3
242	Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration. <i>European Journal of Health Economics</i> , 2019, 20, 475-482.	1.4	1
243	Quasi-experimental design. <i>Biostatistics and Epidemiology</i> , 2020, 4, 38-47.	0.4	58
244	Heterogeneous Exposure Associations in Observational Cohort Studies: The Example of Blood Pressure in Older Adults. <i>American Journal of Epidemiology</i> , 2020, 189, 55-67.	1.6	3
245	Subgroup balancing propensity score. <i>Statistical Methods in Medical Research</i> , 2020, 29, 659-676.	0.7	29
246	Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. <i>Clinical Trials</i> , 2020, 17, 231-234.	0.7	10
247	Re: Selecting Optimal Subgroups for Treatment Using Many Covariates. <i>Epidemiology</i> , 2020, 31, e30-e31.	1.2	2
248	An approach to explore for a sweet spot in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2020, 120, 59-66.	2.4	1
249	Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach. <i>Heart</i> , 2020, 106, 261-266.	1.2	10
250	Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 132-141.	3.7	23
251	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. <i>Lancet, The</i> , 2020, 396, 1399-1412.	6.3	120
252	Combinatorial Action of Temporally Segregated Transcription Factors. <i>Developmental Cell</i> , 2020, 55, 483-499.e7.	3.1	36
253	Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations. <i>Clinical Trials</i> , 2020, 17, 729-731.	0.7	1
254	Why clinical trials may not help patients make treatment decisions: results from focus group discussions with 22 patients. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 651-658.	0.6	0

#	ARTICLE	IF	CITATIONS
255	Comparative effectiveness of direct admission and admission through emergency departments for children: a randomized stepped wedge study protocol. <i>Trials</i> , 2020, 21, 988.	0.7	4
256	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020, 172, 35.	2.0	203
257	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. <i>Annals of Internal Medicine</i> , 2020, 172, W1.	2.0	83
258	A protocol for chronic pain outcome measurement enhancement by linking PROMIS-29 scale to legacy measures and improving chronic pain stratification. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 671.	0.8	7
259	Predictive approaches to heterogeneous treatment effects: a scoping review. <i>BMC Medical Research Methodology</i> , 2020, 20, 264.	1.4	32
260	Graphing and reporting heterogeneous treatment effects through reference classes. <i>Trials</i> , 2020, 21, 386.	0.7	3
261	The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. <i>Trials</i> , 2020, 21, 542.	0.7	20
262	Identifying subgroups: Part 2: Trajectories of change over time. <i>European Journal of Cardiovascular Nursing</i> , 2020, 19, 444-450.	0.4	10
263	Long-term digital device-enabled monitoring of functional status: Implications for management of persons with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12017.	1.8	4
264	A threshold-free summary index for quantifying the capacity of covariates to yield efficient treatment rules. <i>Statistics in Medicine</i> , 2020, 39, 1362-1373.	0.8	1
265	Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error. <i>Trials</i> , 2020, 21, 156.	0.7	11
266	Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100124.	1.3	6
267	Evaluating heterogeneity of treatment effects. <i>Biostatistics and Epidemiology</i> , 2020, 4, 98-104.	0.4	4
268	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.5	6
269	Pre-Clinical Common Data Elements for Traumatic Brain Injury Research: Progress and Use Cases. <i>Journal of Neurotrauma</i> , 2021, 38, 1399-1410.	1.7	22
270	“Reports of My Death Were Greatly Exaggerated”: Behavior Genetics in the Postgenomic Era. <i>Annual Review of Psychology</i> , 2021, 72, 37-60.	9.9	49
271	Computational medicine, present and the future: obstetrics and gynecology perspective. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 16-34.	0.7	7
272	A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease. <i>Clinical Trials</i> , 2021, 18, 351-360.	0.7	9

#	ARTICLE	IF	CITATIONS
273	Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index. <i>Alzheimer's and Dementia</i> , 2021, 17, 1205-1212.	0.4	23
274	Nortriptyline for pain in knee osteoarthritis: a double-blind randomised controlled trial in New Zealand general practice. <i>British Journal of General Practice</i> , 2021, 71, e538-e546.	0.7	6
275	Which patients benefit most from completing health risk assessments: comparing methods to identify heterogeneity of treatment effects. <i>Health Services and Outcomes Research Methodology</i> , 0, , 1.	0.8	1
276	Long-Term Implications of Abnormal Left Ventricular Strain During Sepsis. <i>Critical Care Medicine</i> , 2021, 49, e444-e453.	0.4	7
277	A Pharmacist and Health Coachâ€“Delivered Mobile Health Intervention for Type 2 Diabetes: Protocol for a Randomized Controlled Crossover Study. <i>JMIR Research Protocols</i> , 2021, 10, e17170.	0.5	5
278	Feasibility and efficacy of a decision aid for emergency department patients with suspected ureterolithiasis: protocol for an adaptive randomized controlled trial. <i>Trials</i> , 2021, 22, 201.	0.7	3
279	Cuestionarios clÃ“nicos para el diagnÃ³stico de la enfermedad pulmonar obstructiva crÃ³nica. RevisiÃ³n sistemÃ¡tica y metaanÃ¡lisis. <i>Revista Facultad De Medicina</i> , 2020, 69, .	0.0	1
280	Increasing risk-concordant cardiovascular care in diverse health systems: a mixed methods pragmatic stepped wedge cluster randomized implementation trial of shared decision making (SDM4IP). <i>Implementation Science Communications</i> , 2021, 2, 43.	0.8	4
281	Heterogeneity Is a Hallmark of Traumatic Brain Injury, Not a Limitation: A New Perspective on Study Design in Rehabilitation Research. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 974-985.	0.9	45
282	Finding associations in a heterogeneous setting: statistical test for aberration enrichment. <i>Genome Medicine</i> , 2021, 13, 68.	3.6	3
283	Experimental Designs to Optimize Treatments for Individuals. <i>JAMA Pediatrics</i> , 2021, 175, 404.	3.3	30
284	A two-stage prediction model for heterogeneous effects of treatments. <i>Statistics in Medicine</i> , 2021, 40, 4362-4375.	0.8	15
285	Propensity score weighting for causal subgroup analysis. <i>Statistics in Medicine</i> , 2021, 40, 4294-4309.	0.8	22
286	Novel treatments for autism spectrum disorder based on genomics and systems biology. , 2022, 230, 107939.		19
287	Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-104.	0.9	11
288	Identifying adults with acute rhinosinusitis in primary care that benefit most from antibiotics: protocol of an individual patient data meta-analysis using multivariable risk prediction modelling. <i>BMJ Open</i> , 2021, 11, e047186.	0.8	1
289	A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint. <i>Statistics in Medicine</i> , 2021, 40, 5961-5981.	0.8	22
290	Single case designs for early phase behavioral translational research in health psychology.. <i>Health Psychology</i> , 2021, 40, 858-874.	1.3	5

#	ARTICLE	IF	CITATIONS
291	Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS ONE, 2021, 16, e0256338.	1.1	2
292	Improving the Estimation of Subgroup Effects for Clinical Trial Participants with Multimorbidity by Incorporating Drug Class-Level Information in Bayesian Hierarchical Models: A Simulation Study. Medical Decision Making, 2022, 42, 228-240.	1.2	2
293	Effect of renal impairment on the efficacy and safety of intra-arterial treatment: A post-hoc analysis of DIRECT-MT study. International Journal of Stroke, 2022, 17, 746-752.	2.9	6
294	Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention. BMC Cardiovascular Disorders, 2021, 21, 435.	0.7	7
295	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	1.8	13
296	Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial. Journal of Pediatrics, 2021, 236, 78-85.e5.	0.9	16
297	Anaesthetic depth and delirium: a challenging balancing act. British Journal of Anaesthesia, 2021, 127, 667-671.	1.5	13
298	Rationale for a Clinical Trial That Compares Acute Stroke Rehabilitation at Inpatient Rehabilitation Facilities to Skilled Nursing Facilities: Challenges and Opportunities. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1213-1221.	0.5	3
299	Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke, 2021, 52, 3258-3265.	1.0	5
300	Chronic pain treatment preferences change following participation in N-of-1 trials, but not always in the expected direction. Journal of Clinical Epidemiology, 2021, 139, 167-176.	2.4	1
301	Translating Comparative Effectiveness Research Evidence to Real-World Decision Making: Some Practical Considerations. , 2017, , 105-116.		1
302	Using observational data for personalized medicine when clinical trial evidence is limited. Fertility and Sterility, 2018, 109, 946-951.	0.5	15
303	Counterfactual clinical prediction models could help to infer individualized treatment effects in randomized controlled trials—An illustration with the International Stroke Trial. Journal of Clinical Epidemiology, 2020, 125, 47-56.	2.4	16
304	Multimorbidity in randomized controlled trials of behavioral interventions: A systematic review.. Health Psychology, 2019, 38, 831-839.	1.3	18
305	Improving Veteran Access to Integrated Management of Back Pain (AIM-Back): Protocol for an Embedded Pragmatic Cluster-Randomized Trial. Pain Medicine, 2020, 21, S62-S72.	0.9	7
306	Implications of Practice Variability. Anesthesiology, 2020, 132, 606-608.	1.3	11
308	Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Medicine, 2017, 14, e1002410.	3.9	60
309	Mixing Nulliparous and Multiparous Women in Randomised Controlled Trials of Preeclampsia Prevention Is Debatable: Evidence from a Systematic Review. PLoS ONE, 2013, 8, e66677.	1.1	5

#	ARTICLE	IF	CITATIONS
310	A Systematic Review on the Development of Asthma and Allergic Diseases in Relation to International Immigration: The Leading Role of the Environment Confirmed. PLoS ONE, 2014, 9, e105347.	1.1	85
311	Effects of a population-based, person-centred and integrated care service on health, wellbeing and self-management of community-living older adults: A randomised controlled trial on Embrace. PLoS ONE, 2018, 13, e0190751.	1.1	42
312	Concerning the "repression" of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine. Farmakoekonomika, 2019, 12, 91-114.	0.4	12
313	Patient Perceptions of Their Own Data in mHealth Technology-Enabled N-of-1 Trials for Chronic Pain: Qualitative Study. JMIR MHealth and UHealth, 2018, 6, e10291.	1.8	25
314	An Intervention Delivered by App Instant Messaging to Increase Acceptability and Use of Effective Contraception Among Young Women in Bolivia: Protocol of a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e252.	0.5	12
315	Routine low-dose continuous or nocturnal oxygen for people with acute stroke: three-arm Stroke Oxygen Supplementation RCT. Health Technology Assessment, 2018, 22, 1-88.	1.3	6
316	Indomethacin for post-endoscopic retrograde cholangiopancreatography pancreatitis prophylaxis: Is it the magic bullet?. World Journal of Gastroenterology, 2012, 18, 4082.	1.4	4
317	Tools and Techniques " Statistical. Confounding and effect measure modification: analysing sex in cardiovascular research. EuroIntervention, 2016, 12, 404-407.	1.4	1
318	A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 891-901.	2.5	38
319	Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis. BMJ, The, 2021, 375, n2183.	3.0	64
320	Continuous Infusion of Fluid Hydration Over 24 Hours Does Not Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Digestive Diseases and Sciences, 2021, , 1.	1.1	1
321	Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurology, The, 2021, 20, 907-916.	4.9	44
327	Patent foramen ovale: the known unknowns. EuroIntervention, 2019, 14, 1350-1352.	1.4	0
332	An Intervention Delivered by Mobile Phone Instant Messaging to Increase Acceptability and Use of Effective Contraception Among Young Women in Bolivia: Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e14073.	2.1	13
333	Bias, coverage, and asymptotic behaviour of random effects meta-analysis. International Journal of Evidence-Based Healthcare, 2020, Publish Ahead of Print, .	0.1	1
335	Precision Medicine in Critical Illness: Sepsis and Acute Respiratory Distress Syndrome. Respiratory Medicine, 2020, , 267-288.	0.1	2
336	Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine. American Health and Drug Benefits, 2012, 5, 310-7.	0.5	12
337	EFFICACY-TO-EFFECTIVENESS CLINICAL TRIALS. Transactions of the American Clinical and Climatological Association, 2018, 129, 279-300.	0.9	4

#	ARTICLE	IF	CITATIONS
338	Optimal Time of Collapse to Return of Spontaneous Circulation to Apply Targeted Temperature Management for Cardiac Arrest: A Bayesian Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 784917.	1.1	7
339	Assessment of Comorbidity Burden and Treatment Response: Reanalysis of the SCD-HEFT Trial. <i>Drugs and Aging</i> , 2022, 39, 165-173.	1.3	3
340	An individualized decision between physical therapy or surgery for patients with degenerative meniscal tears cannot be based on continuous treatment selection markers: a marker-by-treatment analysis of the ESCAPE study. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2022, 30, 1937-1948.	2.3	6
341	Quality of biomarker defined subgroups in <scp>FDA</scp> approvals of <scp>PD</scp> inhibitors 2014 to 2020. <i>International Journal of Cancer</i> , 2022, 150, 1905-1910.	2.3	3
342	Young Swiss men's risky single-occasion drinking: Identifying those who do not respond to stricter alcohol policy environments. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109410.	1.6	1
343	Patent Foramen Ovale Closure—Harnessing Clinical Trial Evidence to Inform Individualized Treatment Decisions. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2265.	3.8	3
346	Development, evaluation and implementation of a digital behavioural health treatment for chronic pain: study protocol of the multiphase DAHLIA project. <i>BMJ Open</i> , 2022, 12, e059152.	0.8	7
347	Personalizing Medicine. , 2022, , 37-59.		0
349	The Value of Patient Registries to Advance Basic and Translational Research in the Area of Traumatic Brain Injury. <i>Frontiers in Behavioral Neuroscience</i> , 2022, 16, 846919.	1.0	8
350	Building causal knowledge in behavior genetics. <i>Behavioral and Brain Sciences</i> , 2023, 46, 1-76.	0.4	12
351	Analgesic and Anxiolytic Effects of Virtual Reality During Minor Procedures in an Emergency Department: A Randomized Controlled Study. <i>Annals of Emergency Medicine</i> , 2023, 81, 84-94.	0.3	5
353	Health-related quality-of-life and health-utility reporting in critical care. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 236-245.	0.8	4
354	Towards assessing agricultural land suitability with causal machine learning. , 2022, , .		2
355	Genetic heterogeneity: Challenges, impacts, and methods through an associative lens. <i>Genetic Epidemiology</i> , 2022, 46, 555-571.	0.6	12
356	Acupuncture versus massage for pain in patients living with advanced cancer: a protocol for the IMPACT randomised clinical trial. <i>BMJ Open</i> , 2022, 12, e058281.	0.8	2
357	New insight into the analgesic recipe: A cohort study based on smart patient-controlled analgesia pumps records. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
358	Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study. <i>ESC Heart Failure</i> , 2023, 10, 322-333.	1.4	3
359	Mediators, Moderators, and Covariates: Matching Analysis Approach for Improved Precision in Cognitive-Communication Rehabilitation Research. <i>Journal of Speech, Language, and Hearing Research</i> , 2022, 65, 4159-4171.	0.7	3

#	ARTICLE	IF	CITATIONS
360	State-of-the-Art Evidence Retriever for Precision Medicine: Algorithm Development and Validation. JMIR Medical Informatics, 2022, 10, e40743.	1.3	2
361	Decision Curve Analysis for Personalized Treatment Choice between Multiple Options. Medical Decision Making, 2023, 43, 337-349.	1.2	8
362	Behavioural intervention to reduce sexually transmitted infections in people aged 16–24 years in the UK: the safetxt RCT. Public Health Research, 2023, 11, 1-96.	0.5	1
364	Assessing Heterogeneity of Treatment Effect in Real-World Data. Annals of Internal Medicine, 2023, 176, 536-544.	2.0	4
366	Telehealth-Based Music Therapy Versus Cognitive Behavioral Therapy for Anxiety in Cancer Survivors: Rationale and Protocol for a Comparative Effectiveness Trial. JMIR Research Protocols, 0, 12, e46281.	0.5	0
367	Statistical and methodological considerations for randomized-controlled trial design in physical medicine and rehabilitation. American Journal of Physical Medicine and Rehabilitation, 0, Publish Ahead of Print, .	0.7	0
368	Occupational Performance Coaching for Children With Neurodisability: A Randomized Controlled Trial Protocol. Canadian Journal of Occupational Therapy, 2024, 91, 4-16.	0.8	1
369	Barriers and Facilitators of Evidence-Based Psychotherapies for Chronic Pain in Adults: A Systematic Review. Journal of Pain, 2023, 24, 742-769.	0.7	2
370	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2023, 329, 1066.	3.8	25
371	Estimating individualized treatment effects from randomized controlled trials: a simulation study to compare risk-based approaches. BMC Medical Research Methodology, 2023, 23, .	1.4	1
372	A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases. Npj Digital Medicine, 2023, 6, .	5.7	0
373	Overcoming cohort heterogeneity for the prediction of subclinical cardiovascular disease risk. IScience, 2023, 26, 106633.	1.9	1